Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada on ephedra

This article was originally published in The Tan Sheet

Executive Summary

Recalled ephedra items are still available "under the counter, in back rooms and at gyms," agency states in June 9 1advisory asking consumers to report such activities. Health Canada recalled certain ephedra products last year (2"The Tan Sheet" Jan. 14, 2002, p. 16)...

You may also be interested in...

Canada warns on ephedra, kava

Health Canada advises Aug. 21 that two unauthorized natural health products with ephedrine and kava could cause "serious adverse health effects including death." Life Choice Ephedrine HCL "contains an excessive amount of ephedrine," which may react adversely to caffeine or other stimulants, and has been found to be contaminated with bacteria, the agency reports in a same-day release. Health Canada recalled certain ephedra products in 2002 and currently advises their use only for nasal decongestion (1"The Tan Sheet" June 16, 2003, In Brief). Consumers should also discontinue use of Life Choice Kava Kava, the agency says, due to concerns of liver toxicity related to consumption of kava products. Health Canada halted Kava product sales in August 2002 and they are also banned in the U.K. (2"The Tan Sheet" Aug. 26, 2002, In Brief and 3"The Tan Sheet" Aug. 7, 2006, In Brief)

Health Canada Nationwide Ephedra Supplement Recall Initiated

Health Canada has stepped up enforcement of ephedra supplements by recalling all products that combine ephedra with caffeine or do not meet recognized dosing and labeling requirements

QUOTED. 19 April 2021. Jeff Shuren & William Maisel

Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts